Dr. Li Zhang is a world-renowned medical oncologist and a leading authority in the treatment of lung cancer and nasopharyngeal carcinoma (NPC). With an illustrious career spanning over 40 years at Sun Yat-sen University Cancer Center, he has been instrumental in bridging the gap between clinical excellence and drug regulatory science in China.

l Precision Oncology: Developing molecular-driven, prognostic, and therapeutic strategies for Lung Cancer and Nasopharyngeal Carcinoma.

l Innovative Drug Development: Leading global and domestic Phase I-III clinical trials for ADCs, bispecific antibodies, and immunotherapies.

l Supportive Care: Pioneering research in cancer pain management and the prevention of chemotherapy-induced nausea and vomiting (CINV).

Professor Zhang has published more than 400 peer review research papers in top tier journals like:NEJM, Lancet, JAMA, BMJ, Nature Review Clinical Oncology, Nature Medicine, Lancet Oncology, Lancet Respiratory Medicine, Cancer Cell, Journal of Clinical Oncology, Annals of Oncology, JAMA Oncology. He also presented abstracts to many major congresses like ASCO, WCLC, ESMO, MASCC meetings. He is an editorial board member of Clinical Lung Cancer, Cancer Communication.

1. Sacituzumab Tirumotecan in EGFR-TKI-Resistant, EGFR-Mutated Advanced Non-Small-Cell Lung Cancer

Wenfeng Fang, Lin Wu, Xiangjiao Meng, Yu Yao, Wei Zuo, Wenxiu Yao, Yanyan Xie, Yu Zhang, Jiuwei Cui, Yongchang Zhang, Xingya Li, Wu Zhuang, Jian Fang, Qiming Wang, Wei Jiang, Kai Li, Yuju Bai, Yongzhong Luo, Fang Ma, Yan Yu, Wei Zheng, Zhentian Liu, Bin Yang, Rui Ma, Yong Fang, Runxiang Yang, Liyan Jiang, Jie Hu, Jiacheng Yang, Yina Diao, Xiaoping Jin, Junyou Ge, Yunpeng Yang,Li Zhang:

NEJM; published on October 2026; Vol 394(1):13-26

2. Izalontamab brengitecan, an EGFR×HER3 bispecific antibody-drug conjugate, versus chemotherapy in heavily pretreated recurrent/metastatic nasopharyngeal carcinoma: a multicentre, randomized, open-label, phase 3 study

Yunpeng Yang; Huaqiang Zhou; Linquan Tang; Sufang Qiu; Yaqian Han; Dongmei Ji; Xiaozhong Chen; Feng Lei; Song Qu; Bin Deng; Lusi Chen; Jianli Huang; Ye Guo; Zhigang Liu; Dongping Chen; Jingao Li; Xiaolei Shu; Yan Qin; Zhichao Fu; Bihui Li; Peng Zhang; Shaoqing Chen; Jinsheng Hong; Yan Wei; Xintian Qin; Shenhong Qu; Kunyu Yang; Daren Lin; Junxian Wang; Lei Yang; Sa Xiao; Hai Zhu; Yi Zhu;Li Zhang

The Lancet 2025; Vol 406(10516):2235-2243

3. Sacituzumab tirumotecan versus docetaxel for previously treated EGFR-mutant advanced non-small-cell lung cancer: open label, randomised, multicentre trial.

Wenfeng Fang, Xingya Li, Qiming Wang, Xiangjiao Meng, Wei Zheng, Longhua Sun, Wenxiu Yao, Wu Zhuang, Yun Fan, Minglei Zhuo, Yongzhong Luo, Zhiye Zhang, Xia Song, Runxiang Yang, Jiacheng Yang, Xiaoping Jin, Yina Diao, Junyou Ge,Li Zhang

BMJ 2025; Vol 389: e085680 

4. The next generation of immunotherapies for lung cancer

Shen Zhao, Hongyun Zhao, and Weiwei Yang,Li Zhang 

Nature Reviews Clinical Oncology 2025; Vol 22(8)592–616

5. A B7H3-targeting antibody-drug conjugate in advanced solid tumors: a phase 1/1b trial

Yuxiang Ma, Yunpeng Yang, Yan Huang, Wenfeng Fang, Jinhui Xue, Xiangjiao Meng, Yun Fan, Siqing Fu, Lin Wu, Yulong Zheng, Jian Liu, Zhihua Liu, Wu Zhuang, Seth Rosen, Song Qu, Bihui Li, Mingjun Li, Yanqiu Zhao, Shujun Yang, Yinghua Ji, David Sommerhalder, Suxia Luo, Kunyu Yang, Jingao Li, Dongqing Lv, Peng Zhang, Yuanyuan Zhao, Shaodong Hong, Yang Zhang, Shen Zhao, Steve Chin, Xian Zhang, Wei Lian, Jiaqiang Cai, Tongtong Xue,Li Zhang, Hongyun Zhao

Nature Medicine 2025; Vol 31(6):1949-1957

6. Sacituzumab tirumotecan (SKB264/MK-2870), a Trop2-directed antibody-drug conjugate, in advanced non-small cell lung cancer with or without EGFR mutations: results from the phase 1/2 KL264-01 and phase 2 SKB264-II-08 studies

Shen Zhao, Ying Cheng, Qiming Wang, Xingya Li, Jun Liao, Jordi Rodon Ahnert, Zhendong Chen, Wei Wang, Tienan Yi, Yongsheng Li, Yongmei Yin, Huiting Xu, Guohua Yu, Yongzhong Luo, Yanjun Mi, Xiangjiao Meng, Yun Fan, Zev A. Wainberg, Xiang Wang, Cuiyun Su, Qitao Yu, Shuzhen Lai, Longhua Sun, Wu Zhuang, Xian Wang, Jiacheng Yang, Yaling Li, Junyou Ge, Jin Li,Li Zhang, Wenfeng Fang:

Nature Medicine 2025; Vol 31(6):1976-1986

7. Randomized, double-blind, double-dummy phase III trial of mixed formulation of fosrolapitant and palonosetron (HR20013) in preventing highly emetogenic chemotherapy-induced nausea and vomiting: PROFIT

Huaqiang Zhou, Yuanyuan Zhao, Mingjun Zhang, Jun Yao, Shuang Leng, Xiumin Li, Li Lin, Jinping Chen, Songnan Zhang, Xia Qin, Zhiquan Qin, Tienan Yi, Ruoyu Wang, Xiang Li, Yan Yu, Zhenghua Wang, Qinhong Zheng, Jiazhuan Mei, Aimin Zang, Na Li, Fengjun Cao, Ke Cao, Weiwei Li, Yanda Lu, Dang Lin, Yan Zhou, Runxiang Yang, Wenfeng Fang, Ningning Zhou, Yunpeng Yang, Yaxiong Zhang, Gang Chen, Ting Zhou, Xue Yang, Huan Wang, Yujiao Wang, Yan Huang,Li Zhang

Journal of Clinical Oncology 2025; Vol 43(9):1123-1136

8. Ivonescimab Plus Chemotherapy in Non–Small Cell Lung Cancer With EGFR Variant A Randomized Clinical Trial.

W Fang, Y Zhao, Y Luo, R Yang, Y Huang, Z He, H Zhao, M Li, K Li, Q Song, X Du, Y Sun, W Li, F Xu, Z Wang, K Yang, Y Fan, B Liu, H Zhao, Y Hu, L Jia, S Xu, T Yi, D Lv, H Lan, M Li, W Liang, Y Wang, H Yang, Y Jia, Y Chen, J Lu, J Feng, C Liu, M Zhou, J Zhou, X Liu, N Zhou, M He, X Dong, H Chen, Y Chen, H Su, X Li, Z Zhang, L Yang, Y Cheng, L Chen, X Hou, Y Zhang, J Guo, Z Wang, H Lu, D Wu, W Feng, W Li, J Huang, Y Wang, X Song, J Peng, L Liu, Y Guo, W Li, D Lu, M Hu, Z Wang, B Li, M Xia,Li Zhang.

JAMA 2024; Vol 332(7):561-570

9. ALESIA: a randomised phase 3 study of alectinib versus crizotinib in untreated Asian patients with anaplastic lymphoma kinase-positive non-small-cell lung cancer.

C Zhou, S Kim, T Reungwetwattana, J Zhou, Y Zhang, J He, J Yang, Y Cheng, S Lee, L Bu, T Xu, L Yang, C Wang, T Liu, P N. Morcos, Y Lu,Li Zhang.

The Lancet Respiratory Medicine 2019

10. Gemcitabine Plus Cisplatin Versus Fluorouracil Plus Cisplatin as First-Line Therapy for Recurrent or Metastatic Nasopharyngeal Carcinoma: Final Overall Survival Analysis of GEM20110714 Phase III Study.

S Hong, Y Zhang, G Yu, P Peng, J Peng, J Jia, X Wu, Y Huang, Y Yang, Q Lin, X Xi, M Xu, D Chen, X Lu, R Wang, X Cao, X Chen, Z Lin, J Xiong, Q Lin, C Xie, Z Li, J Pan, J Li, S Wu, Y Lian, Q Yang, C Zhao, W Fang,Li Zhang.

Journal of Clinical Oncology 2021; Vol 39(29):3273-3282

11. Camrelizumab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (CAPTAIN-1st): a multicentre, randomised, double-blind, phase 3 trial.

Y Yang, S Qu, J Li, C Hu, M Xu, W Li, T Zhou, L Shen, H Wu, J Lang, G Hu, Z Luo, Z Fu, S Qu, W Feng, X Chen, S Lin, W Zhang, X Li, Y Sun, Z Lin, Q Lin, F Lei, J Long, J Hong, X Huang, L Zeng, P Wang, X He, B Zhang, Q Yang, X Zhang, J Zou, W Fang,Li Zhang 

Lancet Oncology 2021; Vol 22(8):1162-1174

12. Efficacy, safety, and biomarker analysis of ensartinib in crizotinib-resistant, ALK-positive nonsmall-cell lung cancer: a multicentre, phase 2 trial.

Y Yang, J Zhou, J Zhou, J Feng, W Zhuang, J Chen, J Zhao, W Zhong, Y Zhao, Y Zhang, Y Song, Y Hu, Z Yu, Y Gong, Y Chen, F Ye, S Zhang, L Cao, Y Fan, G Wu, Y Guo, C Zhou, K Ma, J Fang, W Feng, Y Liu, Z Zheng, G Li, N Wu, W Song, X Liu, S Zhao, L Ding, L Mao, G Selvaggi, X Yuan, Y Fu, T Wang, S Xiao,Li Zhang 

Lancet Respiratory Medicine 2020; Vol 8(1):45-53

13. Gemcitabine plus cisplatin versus fl uorouracil plus cisplatin in recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 trial.

Li Zhang, Y Huang, S Hong, Y Yang, G Yu, J Jia, P Peng, X Wu, Q Lin, X Xi, J Peng, M Xu, D Chen, X Lu, R Wang, X Cao, X Chen, Z Lin, J Xiong, Q Lin, C Xie, Z Li, J Pan, J Li, S Wu, Y Lian, Q Yang, C Zhao